Stock Scorecard



Stock Summary for Bausch Health Companies Inc (BHC) - $5.88 as of 2/6/2026 7:22:24 PM EST

Total Score

14 out of 30

Safety Score

35 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for BHC

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BHC

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BHC

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BHC

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BHC (35 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BHC

Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results 2/6/2026 10:34:00 AM
Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results 2/6/2026 10:34:00 AM
Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million 2/4/2026 9:29:00 PM
Nebraska Attorney General’s Office Announces Settlements with Lannett and Bausch Totaling $17.85 Million Over Conspiracies to Inflate Prices and Limit Competition 2/4/2026 9:30:00 AM
Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; Sues Novartis and Sandoz 2/3/2026 11:14:00 PM
Arizona AG announces settlements over generic drug prices 2/3/2026 11:58:00 AM
Lannett and Bausch Drug Price Fixing Deal Reaches $17.85M Multistate Settlement 2/2/2026 8:58:00 PM
Colorado and coalition strike a deal with drug companies accused of price-fixing 2/2/2026 4:32:00 PM
Phase 3 RED-C Miss for Hepatic Encephalopathy Prevention Might Change The Case For Investing In Bausch Health Companies (BHC) 1/31/2026 11:58:00 AM
Phase 3 RED-C Miss for Hepatic Encephalopathy Prevention Might Change The Case For Investing In Bausch Health Companies (BHC) 1/31/2026 2:31:00 AM

Financial Details for BHC

Company Overview

Ticker BHC
Company Name Bausch Health Companies Inc
Country USA
Description Bausch Health Companies Inc. (BHC), based in Laval, Canada, is a leading global healthcare firm dedicated to the development, manufacturing, and marketing of innovative pharmaceutical and medical device solutions. The company's core therapeutic areas include eye health, gastroenterology, and dermatology, all aimed at addressing significant medical needs and enhancing patient outcomes. With a robust pipeline focused on research and development and an ongoing commitment to market expansion, Bausch Health presents an attractive investment opportunity for institutional investors seeking exposure to growth in the dynamic healthcare industry.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - SPECIALTY & GENERIC
Most Recent Quarter 9/30/2025
Next Earnings Date 2/18/2026

Stock Price History

Last Day Price 5.88
Price 4 Years Ago 6.28
Last Day Price Updated 2/6/2026 7:22:24 PM EST
Last Day Volume 1,356,610
Average Daily Volume 2,233,901
52-Week High 8.69
52-Week Low 4.25
Last Price to 52 Week Low 38.35%

Valuation Measures

Trailing PE 5.91
Industry PE 46.98
Sector PE 34.82
5-Year Average PE 3.36
Free Cash Flow Ratio 1.63
Industry Free Cash Flow Ratio 11.76
Sector Free Cash Flow Ratio 33.33
Current Ratio Most Recent Quarter 1.30
Total Cash Per Share 3.61
Book Value Per Share Most Recent Quarter -1.52
Price to Book Ratio 18.78
Industry Price to Book Ratio 3.01
Sector Price to Book Ratio 53.77
Price to Sales Ratio Twelve Trailing Months 0.21
Industry Price to Sales Ratio Twelve Trailing Months 3.68
Sector Price to Sales Ratio Twelve Trailing Months 17.66
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 370,517,000
Market Capitalization 2,178,639,960
Institutional Ownership 64.54%

Dividends

Ex-Dividend Date 11/10/2010
Previous Dividend Amount 0.0000
Current Dividend Amount 1.0000
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 5.11
Forward Annual Dividend Yield 68.43%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 1,328.57%
3-Year Dividend Growth Rate Percentage 149.03%
5-Year Dividend Growth Rate Percentage 27.79%
All-Time Dividend Growth Rate Percentage -10.95%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 1,368.00%
Annual Earnings Growth 92.23%
Reported EPS 12 Trailing Months 0.97
Reported EPS Past Year 1.99
Reported EPS Prior Year 2.92
Net Income Twelve Trailing Months 362,000,000
Net Income Past Year -46,000,000
Net Income Prior Year -592,000,000
Quarterly Revenue Growth YOY 6.80%
5-Year Revenue Growth 2.28%
Operating Margin Twelve Trailing Months 26.70%

Balance Sheet

Total Cash Most Recent Quarter 1,338,693,768
Total Cash Past Year 1,181,000,000
Total Cash Prior Year 947,000,000
Net Cash Position Most Recent Quarter -19,124,306,232
Net Cash Position Past Year -17,761,000,000
Long Term Debt Past Year 18,942,000,000
Long Term Debt Prior Year 21,938,000,000
Total Debt Most Recent Quarter 20,463,000,000
Equity to Debt Ratio Past Year -0.07
Equity to Debt Ratio Most Recent Quarter -0.03
Total Stockholder Equity Past Year -1,279,000,000
Total Stockholder Equity Prior Year -1,022,000,000
Total Stockholder Equity Most Recent Quarter -564,449,238

Free Cash Flow

Free Cash Flow Twelve Trailing Months 1,085,000,000
Free Cash Flow Per Share Twelve Trailing Months 2.93
Free Cash Flow Past Year 1,260,000,000
Free Cash Flow Prior Year 760,000,000

Options

Put/Call Ratio 0.39
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.39
MACD Signal -0.29
20-Day Bollinger Lower Band 5.52
20-Day Bollinger Middle Band 6.54
20-Day Bollinger Upper Band 7.55
Beta 0.38
RSI 29.35
50-Day SMA 6.35
150-Day SMA 7.28
200-Day SMA 7.68

System

Modified 2/6/2026 6:37:33 PM EST